GNLX
Genelux Corporation
There isn't enough reported data to score GNLX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
GNLX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
GNLX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GNLX PE Valuation
GNLX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GNLX Forward outlook
There aren't enough analyst estimates for GNLX to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
GNLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.86 | -$0.01 |
| Q1 2026 | -$0.85 | +$0.02 |
| Q4 2025 | -$0.86 | +$0.09 |
| Q3 2025 | -$0.87 | +$0.03 |
| Q2 2025 | -$0.85 | +$0.06 |
| Q1 2025 | -$0.87 | +$0.05 |
| Q4 2024 | -$0.95 | +$0.21 |
| Q3 2024 | -$0.90 | +$0.19 |
GNLX is still losing money, but less than at its worst: $0.86 per share over the past year, against $1.16 at its worst in late 2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over GNLX on earnings quality, reporting a profit while its opponent remains loss making.
GNLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2024 | $8K | -95% |
GNLX's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2024 | -101438% | -97636 points |
| Q1 2023 | -3801% | N/A |
| Q4 2022 | -4550% | N/A |
| Q3 2022 | 58% | N/A |
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
GNLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$8M | -$802K |
| Q1 2026 | -$7M | -$1.5M |
| Q4 2025 | -$6.6M | -$2.2M |
| Q3 2025 | -$7.1M | -$1.3M |
| Q2 2025 | -$7.2M | -$122K |
| Q1 2025 | -$5.5M | -$1.1M |
| Q4 2024 | -$4.4M | +$2.8M |
| Q3 2024 | -$5.8M | -$2.1M |
GNLX has burned cash in almost every quarter: −$29M over the past year, against −$23M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over GNLX on cash generation, producing positive trailing cash flow while its opponent burns cash.
GNLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +808K shares |
| 1 year | +18% | +7M shares |
| 3 years | +79% | +19.9M shares |
| 5 years | +111% | +23.7M shares |
| Available history | +90% | +21.3M shares |
GNLX has 45M diluted shares, up 18% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over GNLX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GNLX Net Leverage
GNLX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GNLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.8 | Neutral |
| Stochastic | 14.5 | Oversold |
GNLX's weekly RSI is 31 (neutral) and its Stochastic is 15 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GNLX PE vs Healthcare Sector
GNLX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GNLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.25 | 16% below |
| 20 week MA | $2.55 | 25% below |
| 50 week MA | $2.84 | 33% below |
| 100 week MA | $3.29 | 42% below |
LLY has stronger trend alignment. GNLX is above 0 of 4 weekly averages versus LLY above 5 of 5.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
GNLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $6.01 | $14.0 | +133% |
| 2024 | $14.0 | $2.48 | -82% |
| 2025 | $2.48 | $4.37 | +76% |
| 2026 YTD | $4.37 | $1.90 | -57% |
GNLX's yearly returns have swung widely, from +133% in 2023 to −82% in 2024. It's down 57% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over GNLX on returns for 2026, with the stronger performance.